Simplex Trading
JANX icon

Simplex Trading’s Janux Therapeutics JANX Stock Holding History

Simplex Trading’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$759K Buy
54,600
+32,600
+148% +$447K ﹤0.01% 2788
2025
Q4 		$304K Buy
22,000
+21,900
+21,900% +$515K ﹤0.01% 3799
2025
Q3 		$2K Sell
100
-3,300
-97% -$80.4K ﹤0.01% 8657
2025
Q2 		$78K Buy
3,400
+600
+21% +$15.8K ﹤0.01% 5472
2025
Q1 		$75K Sell
2,800
-7,500
-73% -$283K ﹤0.01% 5380
2024
Q4 		$551K Buy
10,300
+8,100
+368% +$428K ﹤0.01% 3424
2024
Q3 		$99K Sell
2,200
-14,700
-87% -$640K ﹤0.01% 5241
2024
Q2 		$707K Buy
16,900
+10,100
+149% +$474K ﹤0.01% 3274
2024
Q1 		$256K Buy
+6,800
New +$148K ﹤0.01% 4579
2023
Q1 		– Sell
-1,100
Closed -$14K – 9558
2022
Q4 		$14K Buy
1,100
+100
+10% +$1.46K ﹤0.01% 7214
2022
Q3 		$2K Buy
+1,000
New +$13.4K ﹤0.01% 9291

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Simplex Trading's JANX Position: Q1 2026 in Review

Simplex Trading sold out of Janux Therapeutics (JANX) in Q1 2026, closing a stake of 17,567 shares — an estimated $241K sold.

Simplex Trading first reported a position in JANX in Q4 2022 and held it in 6 quarters. The position peaked at $260K in Q1 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • Simplex Trading reported no remaining Janux Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Simplex Trading sold 17,567 Janux Therapeutics shares in Q1 2026, an estimated $241K.
  • Simplex Trading first reported a position in Janux Therapeutics in Q4 2022 and held it in 6 quarters.
  • Simplex Trading's Janux Therapeutics position peaked at $260K in Q1 2024.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.